Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 21,235 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity Disorders Clear all

Conditions: Chronic Pain, Back Pain Lower Back Chronic, Back Pain, Low
Interventions: Open-Label Placebo Treatment for Chronic Back Pain, Psychotherapy Treatment for Chronic Back Pain; Other · Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 21 Years to 70 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Breast Cancer
Interventions: Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl); Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elranatamab, GM-CSF, DC/MM Fusion Vaccine; Drug · Biological
Lead sponsor: David Avigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia
Interventions: Polyphenon E; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Lymphomas, Tumors
Interventions: Irinotecan; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Year to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hiv
Interventions: Clinics remodeling; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes
Interventions: Questionnaires; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 9 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 37 more

Conditions: HIV/AIDS, HIV-1-infection, Osteopenia
Interventions: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen; Drug
Lead sponsor: Philip Grant; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 7 more

Conditions: HIV Infections, Sexual Behavior
Interventions: Keeping it LITE; Other
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 13 Years to 34 Years
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: Therapeutic Cellular Vaccine, GM-CSF Producing; Biological
Lead sponsor: Cell Genesys; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C Virus
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 815,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Islatravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma, Lymphoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
Interventions: A-007; Drug
Lead sponsor: DEKK-TEC, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 69
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more

Conditions: Leukemia, Lymphocytic, Acute
Interventions: bone marrow aspiration, peripheral blood sampling; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infection
Interventions: Indinavir, Zidovudine, Lamivudine, Nevirapine, Blood testing, Lymph node biospy, Leukapheresis; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions: beta-glucan, rituximab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 162
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more

Conditions: Lung Diseases
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lupus Nephritis
Interventions: BMS-986165, Placebo, Mycophenolate Mofetil; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 40
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more

Conditions: Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
Interventions: Teprotumumab Injection [Tepezza]; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Mind-body Treatments for Chronic Back Pain

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

Welcoming by Design Pilot: Reducing Structural Stigma by Changing Clinic Systems and Architectural Design

Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Keeping it LITE: Exploring HIV Risk in Vulnerable Youth With Limited Interaction and Digital Health Intervention

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Prediction of Expected Length of Hospital Stay Using Machine Learning

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction